Lisinopril liquid - Silvergate Pharmaceuticals

Drug Profile

Lisinopril liquid - Silvergate Pharmaceuticals

Alternative Names: Lisinopril oral solution; Qbrelis

Latest Information Update: 02 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Silvergate Pharmaceuticals
  • Class Antihypertensives; Heart failure therapies; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure; Hypertension; Myocardial infarction

Most Recent Events

  • 26 Oct 2016 Launched for Heart failure (Adjunctive treatment) in USA (PO)
  • 26 Oct 2016 Launched for Hypertension (In adolescents, In children, In adults) in USA (PO)
  • 26 Oct 2016 Launched for Myocardial infarction in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top